To date, a method by which drugs will be rated depending on factors such as the overall desired and side effects of the drug, as well as its cost, is being looked into by the American Society of Clinical Oncology. It is primarily because while some drugs can prolong a patient's life by mere months, the expenses can balloon to more than a thousand dollars already.
According to the Chief of Hematology and Oncology Dr. Neal Meropol, the sustainability of providing quality health care to cancer patients is difficult to maintain as the high prices can block access to such services.
